Question explored with the scientific record
are there any risks from retatrutide and tesamorelin?
The short version: retatrutide has a confirmed heart-rate and arrhythmia signal that makes the cardiovascular risk real, while tesamorelin’s main documented risk is that stopping reverses its benefits and leaves you with elevated IGF-1.
Retatrutide is a triple agonist (GLP-1, GIP, glucagon) still in phase 3 trials, with manufacturer-funded studies dominating the record. In the phase 2 obesity trial, heart rate rose about 5.6 beats per minute and arrhythmias hit 4 to 14 percent of patients, compared to 2 to 3 percent on placebo [2]. A separate lab study on human heart tissue confirmed retatrutide directly increases the force of atrial contraction through a cAMP mechanism [5] – that is a plausible mechanism for arrhythmia, not just a statistical blip. The network meta-analysis found a relative risk of any adverse event of about 4.1 for retatrutide versus placebo, worse than tirzepatide at 2.78 [1]. Gastrointestinal side effects are common, up to 60 percent nausea at high doses, and discontinuation was 16 to 17 percent versus 0 to 4 percent on placebo [2].
Tesamorelin is a growth-hormone-releasing hormone analog, studied mostly in HIV patients with abdominal fat. It reduces visceral fat by about 21 to 28 square centimeters in 26 weeks, but the benefit fades when you stop the drug [3]. IGF-1 levels rise sharply – over 100 nanograms per milliliter – which is a theoretical risk for diabetes and cancer growth, though the trials did not run long enough to see those outcomes [3]. The data on tesamorelin is older, from 2011, and no long-term safety studies exist for a general weight-loss population. The evidence reviewed here does not include a single comparative safety trial in healthy adults using tesamorelin for non-HIV weight loss. That absence is the main risk to weigh.
The chart below shows the key safety numbers from the retatrutide trials, because that is where the hard data lives.
| Safety outcome | Retatrutide (range) | Placebo |
|---|---|---|
| Heart rate increase | +5.6 bpm [2] | minimal |
| Arrhythmia rate | 4–14% [2] | 2–3% |
| Adverse event relative risk vs placebo | 4.1 (RR) [1] | 1 (reference) |
| Nausea (high dose vs placebo) | 60% [2] | 11% |
| Discontinuation due to side effects | 16–17% [2] | 0–4% |
My call: the risk from retatrutide is measurable and mechanistically supported – do not ignore the heart rate and arrhythmia signals. For tesamorelin, the evidence is too thin in a general population to judge real long-term harm. Confidence: moderate for retatrutide’s cardiovascular risk; not clear for tesamorelin outside HIV lipodystrophy.
Sources examined 8
-
SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials
This network meta-analysis compares tirzepatide and retatrutide for weight loss across randomized trials, finding retatrutide yields greater weight loss but with more adverse events than tirzepatide and highlighting the need for direct head-to-head trials.
DOI: 10.1210/jendso/bvaf149.169 -
Retatrutide as a Novel Treatment for Obesity and Type 2 Diabetes
Retatrutide, a weekly triple agonist of GLP-1, GIP, and glucagon receptors, produced dose-related weight loss and HbA1c reductions in two phase 2 trials (obesity and type 2 diabetes) but showed notable GI and cardiovascular safety signals, underscoring the need for phase 3 confi…
DOI: 10.19080/crdoj.2023.16.555949 -
Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy
This review article describes the HIV lipodystrophy syndrome and critically evaluates growth hormone–related therapies, highlighting that tesamorelin modestly reduces visceral adipose tissue in HIV-infected adults with abdominal fat accumulation (with IGF-1 elevations and potent…
DOI: 10.2147/HIV.S14561 -
Effects of Retatrutide on Learning and Memory in Streptozotocin-Induced Diabetic Rats
Triple incretin receptor agonist Retatrutide partially protects learning and memory and reduces neuroinflammation in STZ-induced diabetic rats, with cognitive benefits occurring alongside incomplete glycemic normalization and partial preservation of brain structure.
DOI: 10.64898/2026.01.23.701347 -
Inotropic effects of retatrutide in isolated human atrial preparations
Retatrutide directly enhances atrial contraction in isolated human right atrial tissue by activating GLP-1R, GCGR, and GIPR, an effect amplified by phosphodiesterase III inhibition and attenuated by receptor antagonists, indicating a cAMP-mediated mechanism with potential clinic…
DOI: 10.1007/s00210-025-04421-3 -
Emerging concepts in obesity management: focus on glucagon receptor agonist combinations
GCGR-based multi-agonists—mazdutide, pemvidutide, survodutide and retatrutide—achieve substantial, dose-dependent weight loss in obesity across phase II/III trials with generally tolerable GI side effects, while long-term safety, durability, and real-world access remain to be de…
DOI: 10.7573/dic.2025-4-8 -
Comparative Efficacy of Dual and Triple GLP-1, GIP, and Glucagon Receptor Agonists: A Systematic Review and Network Meta-analysis
Systematic review and network meta-analysis shows dual and triple GLP-1, GIP, and glucagon receptor agonists improve weight and glycemic outcomes in adults with overweight/obesity or type 2 diabetes, with tirzepatide delivering the strongest glycemic/weight reductions, retatruti…
DOI: 10.54097/9576k069 -
Mechanisms of Glucagon Receptor Agonism and GLP-1/Glucagon/GIP Receptor Triple Agonism for Treatment of Diabetes and Obesity
This narrative review summarizes the pharmacology and development of glucagon receptor agonists and GLP-1/Glucagon/GIP triple receptor agonists, detailing mechanistic insights and preclinical/clinical evidence for obesity and type 2 diabetes therapies along with safety considera…
DOI: 10.4093/jkd.2024.25.2.82